GeneLancet Biosciences is pleased to announce that Paul Schroeder has joined as Contract Chief Business Officer.
Paul brings strong business development and corporate strategy experience from senior roles at BioMarin Pharmaceutical Inc. and global BD leadership at Abbott Diabetes Care, along with prior strategic advisory and CDMO-related work. He holds an MBA from the University of San Francisco, a B.S. in Microbiology from Michigan State University, and is a CFA charterholder.
We look forward to his contributions as we advance our LgRNA and STAR platforms.
Leave a Reply